All posts by imreal

NJ Top Docs is Proud To Award Orthopedic Surgeon, Dr. Paul Kovatis As A Top Doc For 2022


Paul Kovatis, MD of Cahill Orthopedic Sports Medicine and Joint Replacement

Paul Kovatis, MD of Cahill Orthopedic Sports Medicine and Joint Replacement

Orthopedic Surgeon, Paul E. Kovatis, MD has been reviewed and approved by NJ Top Docs for 2022. Dr. Kovatis is a part of the Cahill Orthopedic Sports Medicine and Joint Replacement team. Here, Dr. Kovatis provides Cahill Orthopedics with foot and ankle experience, reputation, knowledge and training encompassing all aspects of the leg, foot, and ankle. His expertise ranges from trauma, fractures, to elective surgeries and day to day maladies.

In addition to working at Cahill Orthopedics, Dr. Kovatis is a Fellow and Alumni Educator at the Hospital for Special Surgery. He was also the Past President and Chair of the Medical board and Medical Staff at Hackensack UMC. Dr. Kovatis is the only orthopedic surgeon to ever serve all of these positions concurrently at HUMC.

Due to his expertise, Dr. Kovatis is often referred to cases from attorney compensation boards and second opinions.

Notably, Dr. Kovatis performed the first Bilateral Total Ankle Replacement at HUMC in 2013 and his patient continues to walk, play golf daily, and lead an active lifestyle 8 years post-op.

Dr. Kovatis has been a member of the NYC orthopedic teams treating the New York City Ballet, American Ballet Theatre, various Broadway productions, and both New York baseball teams. He was honored numerous times for his work with the aforementioned performers and athletes.

His orthopedic publications remain in various orthopedic teaching textbooks and he continues to teach residents at the Hospital for Special Surgery in New York.

Dr. Kovatis is a passionate supporter and speaker with various military organizations as well as local law enforcement groups. In fact, five members of his immediate family are buried with numerous honors at the Arlington National Cemetery.

To learn more about Dr. Paul Kovatis and his many accolades, please visit: https://njtopdocs.com/nj-doctors/drpaulkovatis/

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



What Everyone Needs to Know About Saving a Life


Survival depends largely on bystander intervention

Imagine the countless lives we could save if people understood the importance of Calling 911, starting CPR, and using an AED.

Each October, people add a little more pink to their lives as they bring awareness to those affected by breast cancer. With no disrespect to the color pink, the Sudden Cardiac Arrest Foundation is asking everyone to consider adding a little red too.

October is National Sudden Cardiac Arrest Awareness Month. Did you know that Sudden Cardiac Arrest (SCA) is a major public health crisis? It affects about 1,000 people outside hospital settings every day in the U.S. Sadly, survival to hospital discharge after EMS-treated out-of-hospital cardiac arrest (OHCA) is only about 10 percent.

One of the key challenges to reducing death and disability from OHCA is that survival largely depends on immediate action by people nearby who recognize the life-threatening emergency and decide to help. When bystanders provide hands-only CPR (cardiopulmonary resuscitation), survival rates triple to about 30 percent. When bystanders provide CPR, have access to, and use the nearest AED (automated external defibrillator), survival rates increase to about 50 percent.

When SCA occurs, the heart stops without warning. The person collapses and does not respond or breathe normally. They may gasp or shake as if having a seizure. SCA leads to death in minutes if the person doesn’t get help right away. Survival depends largely on the immediate action of people nearby who call 911, start CPR, and use an automated external defibrillator, or AED, when available.

Unfortunately, bystander action is limited. Only four in 10 victims receive bystander CPR and only one in 10 victims is treated with an AED before EMS arrives at the scene. Why don’t more people apply these fundamental lifesaving skills? Seven common myths may be barriers to understanding and action.

MYTH No. 1: SCA is rare. FACT: The number of people who die from SCA every day is equivalent to the number who would die if two jet planes crashed every day and killed nearly everyone on board.

MYTH No. 2: SCA is the same as a heart attack. FACT: When people have heart attacks, they are awake and their hearts are beating. When people have SCA, they are not awake and their hearts are not beating.

MYTH No. 3: SCA only happens to the elderly. FACT: SCA happens to people of all ages, including 23,000 youth each year.

MYTH No. 4: SCA only happens to people with a history of heart problems. FACTt: SCA is often the first indication of a heart problem.

MYTH No. 5: It is better to wait until professional help arrives. FACT: The victim’s outcome is often determined before EMS arrives.

MYTH No. 6: Only trained personnel are allowed to use AEDs. FACT: AEDs are lifesaving devices with visual and voice prompts that are designed for use by laypersons.

MYTH No. 7: AEDs can hurt people by shocking them inappropriately. FACT: AEDs are safe and effective and will not shock the heart unless shocks are needed to restore a healthy heartbeat.

“Bystander action in cases of Sudden Cardiac Arrest dramatically improves the likelihood of survival. With greater public awareness and understanding, thousands of lives could be saved every year,” said Mary M. Newman, MS, President of the Sudden Cardiac Arrest Foundation. “And, since 7 in 10 cardiac arrests occur in the home, taking time to learn CPR and how to use an AED could mean the difference between life and death for a loved one.”

Here’s what everyone needs to know. If you encounter someone in Sudden Cardiac Arrest, act quickly and decisively:

1.    CALL: Call 911 and follow dispatcher instructions.

2.    PUSH: Start CPR. Press hard and fast on the center of the chest at a rate of 100-120 beats per minute.

3.    SHOCK: Use the nearest AED as quickly as possible.

“The Sudden Cardiac Arrest Foundation is committed to increasing awareness of Sudden Cardiac Arrest and the importance of immediate bystander action,” Newman added. “Imagine the countless lives we could save if people understood the importance of Calling 911, starting CPR, and using an AED.”

About Sudden Cardiac Arrest Foundation

Sudden Cardiac Arrest Foundation is a national community benefit 501(c)(3) organization. Our vision is to eliminate preventable death and disability from sudden cardiac arrest and support people affected by SCA. Our mission is to raise awareness of SCA and promote initiatives that help save lives through education, research, and community. Sudden Cardiac Arrest Foundation is a proud co-sponsor of the Call-Push-Shock movement. For more information, visit our website.

Share article on social media or email:

Asymmetrex® Discusses Impact of New Technologies for Stem Cell Dosage Determination on Outsourcing for Stem Cell Clinical Trials, Gene Therapy Clinical Trials, and Pharma


Asymmetrex® Presents at OCTNE 2022 in Boston on October 12

Stem cell dosage determination will transform the stem cell clinical trials industry, including its outsourcing.

The OCTNE 2022 conference, taking place in Boston on October 12-13, is one of Arena International’s premiere industry meetings for bringing together sponsors of clinical trials with their outsourcing partners. Most of the content and focus of the meeting will be on how to improve the flow of essential products and services to clinical trial sponsors for the best experiences and medical outcomes for clinical trials subjects and patients.

Like previous OCTNE conferences, the primary focus of the October 2022 event will be outsourcing for pharmaceutical clinical trials. However, each year, as the regenerative medicine field continues to grow, so has the amount of attention given to outsourcing for cell therapy clinical trials, including stem cell therapy trials and gene therapy trials.

In recent years, stem cell biotechnology company Asymmetrex® has been a major proponent and participant for increasing attention in OCTNE conferences to developments in the supply and outsourcing of stem cell clinical trials and gene therapy clinical trials. Gene therapy trials fall under the Asymmetrex® focus for outsourcing, because many gene therapies required the successful genetic-engineering of tissue stem cells, like blood hematopoietic stem cells.

In past OCTNE presentations, Asymmetrex® President & CEO, James L. Sherley, M.D., Ph.D., anticipated the introduction of Asymmetrex’s lead innovation, kinetic stem cell (KSC) counting, into the stem cell marketplace. Now, after Asymmetrex’s introduction of online calculators for determining the specific dosage of therapeutic tissue stem cells in September of this year, Sherley plans to tell OCTNE 2022 attendees that “Stem cell dosage determination will transform the stem cell clinical trials industry, including its outsourcing.”

Asymmetrex is now partnering with automated cell counter producer OMNI Life Science to introduce the first instrument, called the CASY-PLUS, for automated rapid counting of therapeutic tissue stem cells. This capability will enable stem cell clinical trials sponsors to know the exact dosages of the stem cells in the treatments they administer to their patients for the first time in the more than half century history of stem cell medicine. Outsourced suppliers of stem cell products and stem cell culture reagents will soon need to provide dosage data, too.

The pharmaceutical and biopharmaceutical industries are not left out of the benefits of stem cell dosage determination. The KSC counting technology can be deployed for earlier detection of drug candidates that are toxic to stem cells. Stem cell-toxic drugs cause chronic organ failure, which results in an estimated $4 billion loss for pharmaceutical companies each year. With increasing validation of the utility of KSC counting for stem cell clinical trials, Sherley expects that Pharma will eventually join for the benefits of knowing the dosage of stem cells as well.

About Asymmetrex®

Asymmetrex®, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – stem cell-specific quantification and stem cell expansion – that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex® is a member company of the Advanced Regenerative Manufacturing Institute|BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio). The company’s development of online calculators for rapid stem cell counting has been funded by R&D grants from ARMI|BioFabUSA and the National Heart, Lung, and Blood Institute.

Share article on social media or email:

FHU Hosts RAM Dental Clinic, Serves 100+ Area Residents


FHU nursing students take patient vitals during a free pop-up dental clinic in Henderson, Tennessee Friday, Sept. 30, 2022.

The turnout was both a reassurance of my purpose in starting this planning for the clinic and of the need for Remote Area Medical’s services in this area.

Freed-Hardeman University’s Remote Area Medical (RAM®) Chapter made a difference in the lives of approximately 101 individuals by providing services valued at nearly $60,000 during a pop-up dental clinic held Sept. 30 through Oct. 1, 2022, at the National Guard Armory in Henderson.

RAM, FHU’s RAM Chapter and a group of campus and community partners organized resources to bring the pop-up clinic to the area.

“The turnout was both a reassurance of my purpose in starting this planning for the clinic and of the need for Remote Area Medical’s services in this area,” said Cameron Kuhl, an FHU senior business analytics major and former RAM intern.

RAM’s mission is to alleviate suffering and leave patients in a better condition, according to Brad Hutchins, RAM clinic coordinator.

“It takes a village to make all of this happen — from determining the type of care the clinic will offer to flying in our RAM volunteers from all over the country,” Hutchins said. Saying that dental care is one of the most requested services, he added. “In some cases, patients have gone an extended amount of time without care.”

In Henderson, the clinic opened at 6 a.m. Friday. Half of the patients arrived the evening before to wait for the armory’s parking lot gates to open at midnight. Each patient received a call ticket, which determined the order in which they were seen.

When FHU junior Elijah Brewer arrived at the parking lot at 4:30 a.m. Friday to volunteer, he noticed about 50 cars.

“It was eye-opening to see how many people needed the clinic,” said Brewer, a public relations major. “It’s good to make a difference and help people.”

Inside the armory several areas were organized to serve patients. In triage, FHU nursing students helped process paperwork and prioritize patient needs. Once processed, patients waited in a large room with 10 stations separated by white tents, clear plastic and tape on the floor. The area was designated for dental students from University of Tennessee Health Science Center in Memphis to provide patient care under the supervision of professionals. Patients received treatment for toothaches, along with cleanings, fillings and extractions during the two-day clinic.

Melanie Nollen of Henderson arrived at 11:30 p.m. the evening before the clinic opened and was 32nd in line. As she sat and waited her turn while reading a book, she felt only gratitude.

“I feel blessed that it’s here,” said Nolan, unbothered by the sounds of the fans and dental equipment around her. “In my head, it’s like I’m at the beach. I’ll wait for however long it takes to get my dental work done.”

A family member told Vincent Quick of Huntingdon about the clinic. He was No. 26 Friday. He was there to find out if something could be done about his chipped front tooth.

“I only half smile now, and it’s a confidence-breaker for sure,” he said. Quick passed the time by reading a daily men’s Bible. “It’s a blessing for them to come and help us. Their hearts are big.”

Community partners who supported the clinic include FHU Lion’s Pride, FHU through the donated use of the university’s shuttle and Laurel Cottage and Paul Gray residence hall to host RAM volunteers. Jacks Creek Church of Christ, United Methodist Church, Stantonville Church of Christ and the Tennessee State Guard also provided services.

Kuhl’s wish is that even more people could have been served.

“I hope our community will continue to find ways to alleviate the unattended suffering of others in some way,” he said. “At the end of it all, I hope God is praised for what happened over the last few days. A lot of good came to Chester County through this clinic, and I’m humbled to have been a part of it.”

The mission of Freed-Hardeman University is to help students develop their God-given talents for His glory by empowering them with an education that integrates Christian faith, scholarship and service. With locations in Henderson and Memphis, FHU offers associate, bachelor’s, master’s, specialist and doctoral degrees. More information is available at fhu.edu.

RAM is a major nonprofit provider of free pop-up clinics. Its mission is to prevent pain and alleviate suffering by providing free, quality healthcare to those in need. RAM delivers free dental, vision and medical services to underserved and uninsured individuals. Since RAM was founded in 1985, nearly 183,000 volunteers have treated more than 888,500 individuals and delivered more than $181.5 million worth of free healthcare services.

Share article on social media or email:

PDA Partners with SmartSkin to Bring New Technology to Aseptic Processing Training


Smartskin’s technology to protect the integrity of containers across the fill-finish process will enhance the aseptic processing and visual inspection training courses, making them even more unique and valuable.

Parenteral Drug Association, Inc. (PDA) and SmartSkin Technologies announced a partnership to integrate SmartSkin’s data collection technologies with PDA’s aseptic processing and visual inspection training.

SmartSkin is recognized by leading pharmaceutical brands as an innovator. Its technology helps the industry adapt faster and improve production quality by providing timely data from the container’s perspective inside the production process — from the washer to warehousing. This previously unavailable information enables data-driven decisions, improving efficiency, lowering costs, and reducing waste.

Built on a reputation of scientifically reliable and compliant industry best practices, PDA’s hands-on aseptic processing and visual inspection training courses provide new and experienced pharmaceutical professionals with practical information and implementable solutions related to these critical manufacturing operations.

“PDA’s training curriculum is widely acknowledged as the gold standard for the pharmaceutical industry. We have been working closely with them for the past several months and are thrilled to have our technology included as part of their training,” said SmartSkin CEO, Evan Justason. “We have been working hard to understand all aspects of sterile products, aseptic processing, and how to improve quality in pharmaceutical manufacturing. PDA training will ensure industry professionals understand what is now possible.”

“We are always looking to integrate new technologies into our training courses to provide meaningful hands-on experience to our attendees. Smartskin’s technology to protect the integrity of containers across the fill-finish process will enhance the aseptic processing and visual inspection training courses, making them even more unique and valuable,” said PDA VP of Education, David Talmage.

SmartSkin discussed manufacturing and quality assurance issues at the 2022 PDA/FDA Joint Regulatory Conference in Washington earlier this month and showcased its latest product innovations to PDA and FDA members. SmartSkin will also be attending the upcoming PDA Universe of Pre-Filled Syringes and Injection Devices show in Palm Springs, CA, October 18-19.

About PDA:

The Parenteral Drug Association (PDA) is the leading global provider of science, technology, and regulatory information. The PDA creates awareness and understanding of important issues facing the pharmaceutical and biopharmaceutical community and delivers high-quality, relevant education to the industry. Since its founding in 1946 as a nonprofit organization, PDA has been committed to developing scientifically sound, practical technical information and expertise to advance pharmaceutical/biopharmaceutical manufacturing science and regulation, so members can better serve patients.

About SmartSkin Technologies:

SmartSkin Technologies, Inc. is based in Fredericton, New Brunswick, Canada. The company’s patented Quantifeel™ solutions fuse innovative sensors, deep analytics and artificial intelligence to provide global manufacturers with actionable data on the forces their containers experience during the filling and packaging process. By identifying previously undetectable adverse or abnormal operating conditions, workers are able to better control the process, preventing product defects and costly downtime. SmartSkin’s technology is in use around the world and has earned a reputation as a world leader in IIoT productivity solutions across multiple industries. SmartSkin was honored with the “Best Manufacturing Innovation” at the 2020 PharmaPack Awards in Paris. Learn more at smartskintech.com.

Share article on social media or email:

National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) Programs Receive Reaccreditation


“The public and state regulators can feel confident that an NCCAOM certified practitioner has met nationally recognized standards of competency and safety in acupuncture and Oriental medicine,” said Mina Larson, M.S., MBA, CAE, NCCAOM’s Chief Executive Officer.

NCCAOM first attained NCCA accreditation for its Acupuncture Certification Program in 1991, and the Chinese Herbology Program was subsequently accredited in 1996. The Oriental Medicine Certification Program became accredited for the first time in 2007. To view the NCCA website of accredited certification programs, please go to the NCCA-Accredited Programs Directory.

“NCCA accreditation is another demonstration that NCCAOM’s certification programs are of the highest quality. The public and state regulators can feel confident that an NCCAOM certified practitioner has met nationally recognized standards of competency and safety in acupuncture and Oriental medicine,” said Mina Larson, M.S., MBA, CAE, NCCAOM’s Chief Executive Officer.

NCCA is the accreditation body of the Institute for Credentialing Excellence (ICE). Established in 1977, the NCCA is the leader in setting quality standards for credentialing organizations. NCCA accredits certifying programs based on the highest quality standards in professional certification to ensure that these programs adhere to current standards of practice in the certification industry. Accreditation clearly demonstrates that NCCAOM’s procedures are rigorous and defensible, thus increasing the value of NCCAOM’s certifications. Please visit the ICE website to view NCCA’s standards.

The NCCA standards require demonstration of a valid and reliable process for development, implementation, maintenance, and governance of certification programs. NCCA uses a rigorous peer review process to establish accreditation standards; evaluate compliance with the standards; recognize organizations/programs which demonstrate compliance; and serve as a resource on quality certification. Certification organizations that submit their programs for accreditation are evaluated based on the process and products, and not the content; therefore, the Standards are applicable to all professions and industries. Program content validity is demonstrated by comprehensive job analyses conducted and analyzed by subject matter experts, informed by data gathered from stakeholders in the occupation or industry.

Information about NCCAOM certification programs and a directory of certified practitioners are available at http://www.nccaom.org.

###

The National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) is a non-profit, 501(c)6 tax-exempt organization established in 1982. The mission of NCCAOM is to assure the safety and well-being of the public and to advance and advocate for the professional practice of NCCAOM Board-Certified AcupuncturistsTM by promoting established national standards focused on competence and credentialing.

Share article on social media or email:

Rapidly Growing Integrated Healthcare Company Hires Vice President of Data Analytics


Franz Victoria, VP of Data Analytics at Genuine Health Group

Franz Victoria, V.P. of Data Analytics at Genuine Health Group

I see a bright future as we work in unison.

Genuine Health Group, a Miami-based, integrated healthcare company leading physicians through the industry’s transition to value-based care, welcomes Franz Victoria as its Vice President of Data Analytics. Mr. Victoria was previously a part of the UnitedHealth Group, overseeing the organization’s financial performance and leading medical economics for Florida. He brings more than ten years’ experience to Genuine Health Group.

“Mr. Victoria complements our team at Genuine Health Group,” said Jenifer Montesino, COO of Genuine Health Group. “He will be vital in assessing our organization’s performance and will help identify new ways for innovation and growth. His experience and skillset align perfectly with Genuine Health Group’s mission.”

While at UnitedHealthcare, Mr. Victoria oversaw more than 500,000 Medicare patients in Florida. He saved the company over $65 million through innovative uses of data analytics, which helped him identify medical cost savings opportunities. In addition, Mr. Victoria developed, implemented, and supported the new data warehouse solution for Medicare in 2011 and directed data integration between Preferred Care Partners and Medica Health Plan in 2013.

“This is an exciting opportunity for me,” added Mr. Victoria. “Genuine Health Group energizes me, and I see a bright future as we work in unison.”

In former roles, Mr. Victoria served as a key member of senior finance teams, developed financial models and analytical tools to support objectives and projects, and oversaw the implementation, consolidation, and executive reporting of profit and loss.

As Vice President of Data Analytics at Genuine Health Group, Mr. Victoria will work towards improving physician interactions, identifying new opportunities for analytics, and leveraging opportunities to continue the company’s growth.

For more information on Genuine Health Group, or to schedule an interview with Franz Victoria, please contact Meieli Sawyer at 305-668-0070 or msawyer@weinbachgroup.com.

About Genuine Health Group

Genuine Health Group is an analytics-driven healthcare company that assists physicians and health plans in successfully transitioning to value-based payment models.

Share article on social media or email:

ScribeAmerica to Showcase Expertise and Innovation at MGMA’s 2022 Medical Practice Excellence: Leaders Conference


All three [medical scribe] formats are designed to decrease burnout – a top issue facing healthcare leaders today – increase efficiency, reduce wait times, and transform care team workflow to meet daily outpatient challenges.

ScribeAmerica is pleased to announce its participation in the Medical Group Management Association (MGMA) 2022 Medical Practice Excellence: Leaders Conference on October 9-12 in Boston, Massachusetts. The conference will provide attendees an opportunity to reconnect with peers to solve some of the biggest challenges medical practices face every day, such as provider burnout, improving patient outcomes, minimizing inefficiencies, building winning teams, and optimizing revenue cycles.

Throughout the four-day in-person conference, ScribeAmerica will be showcasing its customizable, comprehensive solutions designed to transform the care team experience. From specialty-specific training to three distinct delivery models available, ScribeAmerica offers scribe and care coordination services designed for clinicians’ unique needs.

ScribeAmerica’s in-person and virtual programs help care teams improve job satisfaction, quality documentation, and productivity across 80 specialties and care settings. Remote solutions include virtual TeleScribes, offering real-time medical scribe access via mobile phone or tablet, as well as Speke Ambient AI Scribe, a scribe-supported, scalable digital assistant. All three formats are designed to decrease burnout – a top issue facing healthcare leaders today – increase efficiency, reduce wait times, and transform care team workflow to meet daily outpatient challenges.

“ScribeAmerica has continued to advance its service offerings over the past several years, offering multiple modalities, including in-person, remote, and ambient AI” said Tony Andrulonis, ScribeAmerica President & Chief Operating Officer. “ We remain at the forefront of innovation, fulfilling our mission to meaningfully impact the well being of providers and patients while improving the integrity of healthcare data.”

The theme of the MGMA Medical Practice Excellence: Leaders Conference is Reaching New Horizons. The conference will bring healthcare professionals together to choose the educational path that fits their day-to-day roles and responsibilities and offers attendees access to the latest healthcare operations, patient care, leadership, and financial education topics. The sessions this year will emphasize interactive elements and allow attendees access to 70 sessions, 120 speakers, and opportunities to network with 2,500+ peers.

For more information about ScribeAmerica, visit scribeamerica.com or follow ScribeAmerica on Instagram, Facebook, Twitter and LinkedIn. Healthcare professionals can register for MGMA here while information on speakers, session details, and schedule for the conference can be found here.

About ScribeAmerica

For nearly 20 years, ScribeAmerica has been the nation’s largest and most progressive medical scribe and care coordination company. Serving over 3,500 partners in all 50 states, our dedicated teams custom design, hire, train and manage programs specific to our partners’ needs.

About MGMA

Founded in 1926, the Medical Group Management Association (MGMA) is the nation’s largest association focused on the business of medical practice management. MGMA consists of 15,000 group medical practices ranging from small private medical practices to large national health systems representing more than 350,000 physicians. MGMA helps nearly 60,000 medical practice leaders and the healthcare community solve the business challenges of running practices so that they can focus on providing outstanding patient care. Specifically, MGMA helps its members innovate and improve profitability and financial sustainability, and it provides the gold standard on industry benchmarks such as physician compensation. The association also advocates extensively on its members’ behalf on national regulatory and policy issues.

Share article on social media or email:



Researchers Identify Flu-Fighting Pathways and Genes Essential for Influenza A Immune Defense


News Image

“Identifying key defense processes and key regulators in multiple species can facilitate the development of treatments for IAV in humans,” – Bin Zhang, PhD, Director of the Center for Transformative Disease Modeling, Professor of Genetics & Genomic Sciences at Icahn Mount Sinai

Researchers have identified the gene TDRD7 as a key regulator against influenza A virus (IAV), which causes respiratory tract infections in 5 to 20 percent of the human population. These findings could facilitate the development of novel therapeutic interventions against influenza virus infection. The study, led by the Icahn School of Medicine at Mount Sinai in collaboration with other institutions, was published in Science Advances (DOI: 10.1126/sciadv.abm5859) on October 5.

IAV is responsible for 250,000-500,000 deaths per year worldwide. When IAV infects its host, an immunological response composed of a series of molecular processes begins. IAV can infect several different species, and physiological and genetic differences among these species can contribute to different host responses, although some responses are shared.

“Identifying key defense processes and key regulators in multiple species can facilitate the development of treatments for IAV in humans,” said Bin Zhang, PhD, Director of the Center for Transformative Disease Modeling, Willard T.C. Johnson Research Professor of Neurogenetics, and Professor of Genetics and Genomic Sciences at Icahn Mount Sinai, who led the study.

The study used RNA sequencing to analyze gene expression over time in cells and tissues collected from IAV-infected humans, ferrets, and mice, identifying multiple key defense processes specific to tissues and species. One gene found to play a key role in immunological defense mechanisms against IAV across all species was TDRD7, which encodes a Tudor domain-containing protein, a type of protein shown to be involved in epigenetic regulation. In light of this discovery, the researchers conducted subsequent experiments inhibiting the function of TDRD7, resulting in an increase of virus replication in IAV-infected models.

“Identifying both common and species-specific responses to influenza is essential in developing effective therapies for the flu and can help inform future research of other respiratory infections, such as COVID-19,” said Christian Forst, PhD, Assistant Professor of Genetics and Genomic Sciences, and Microbiology, at Icahn Mount Sinai and a first author of the study.

Co-first authors on the research team also include Laura Martin-Sancho, PhD, Staff Scientist at Scripps Research, California, and Shashank Tripathi, PhD, Assistant Professor, Microbiology and Cell Biology, Centre for Infectious Disease Research, Indian Institute of Science, Bangalore.

Senior authors on the research team also include Adolfo García-Sastre, PhD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Global Health and Emerging Pathogens Institute at Icahn Mount Sinai in New York, and Elodie Ghedin, PhD, Chief of the Systems Genomics Section and Deputy Chief of the Laboratory of Parasitic Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

This study was supported by the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) under award numbers R21AI149013, U01AI111598, U19AI106754, U19AI135972, U19AI142733, and U19AI168631 and NIAID-funded Center for Research on Influenza Pathogenesis (CRIP) and Center of Excellence for Influenza Research and Response (CEIRR, contract #75N93021C00014).

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 35 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.


  • Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

AHN Administers Updated Moderna and Pfizer COVID-19 Boosters


AHN currently has this year’s influenza vaccine across its primary and pediatric offices, as well, allowing clinicians to administer both doses simultaneously at the patient’s request.

“These vaccination measures to maintain ongoing protection from severe illness and hospitalization due to COVID-19 are now becoming a fundamental component of our patient’s comprehensive wellness plan,” said Laura Mark, vice president of pharmacy at AHN.

Allegheny Health Network (AHN) is now administering the updated Pfizer-BioNTech and Moderna COVID-19 boosters following emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) in late August. The latest series of bivalent vaccinations has been updated to include spike proteins of BA.4 and BA.5, alongside original COVID-19 strains, to better protect against the most recent and highly transmissible Omicron variants.

AHN received updated booster doses in early September and quickly mobilized to transfer shipments across its pediatric and primary care offices throughout western Pennsylvania. The Network officially announced the launch of administration in mid-September.

Those who wish to schedule an appointment for the updated booster or first vaccine may do so by calling 412-DOCTORS, contacting their AHN primary care physician or pediatrics’ office, or reaching out to their local retail pharmacy.

Eligible groups currently include all those over 12 and 18 years of age for Pfizer and Moderna, respectively, who have previously received a primary vaccination series. The CDC also recommends that patients wait at least two months since their last vaccine dose or 90 days from a recent COVID-19 infection to boost.

Both Pfizer and Moderna stated that outcomes reported from late clinical trials showed a dose of its reformulated bivalent vaccine elicited a superior immune response against the original BA.1 and BA.2 COVID-19 strains as well as the currently dominant Omicron variants, all with a favorable safety profile.

Consistent with previous recommendations, the CDC also allows for eligible individuals to opt into “mixing and matching” vaccine brands, stating that those fully immunized with one company’s vaccine, including Johnson & Johnson, may receive a different vaccine as a booster.

“These vaccination measures to maintain ongoing protection from severe illness and hospitalization due to COVID-19 are now becoming a fundamental component of our patient’s comprehensive wellness plan,” said Laura Mark, vice president of pharmacy at AHN. “Now that supply is adequate to meet demand, we encourage our patients to incorporate boosters into their routine visits with their respective physicians, quite similar to how they may approach their annual flu shot. However, it is still critical to underscore how important vaccine acceptance is as we approach the winter season and subsequently prepare for an increase in community spread and hospitalizations due to COVID infections.”

AHN currently has this year’s influenza vaccine across its primary and pediatric offices, as well, allowing clinicians to administer both doses simultaneously at the patient’s request.

Those receiving their booster may experience mostly mild to moderate symptoms which will often mimic the side effects originally felt during their primary series i.e. soreness at the injection site, fever, feeling of general malaise for one to two days, etc.

“Since the start of the COVID-19 vaccination campaign, AHN has worked tirelessly to provide protection for the majority of the population throughout the region,” continued Mark. “That work has created a solid foundation for our ongoing efforts and we look forward to carrying out this most recent vaccination milestone in a streamlined, steady state for both our providers and patients.”

For more information on how to receive the COVID-19 vaccine or booster at an AHN facility near you, please call 412-DOCTORS.

###

Share article on social media or email: